Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Upgraded at Barclays

Barclays upgraded shares of Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) from a strong sell rating to a hold rating in a research report sent to investors on Thursday morning,Zacks.com reports.

Separately, Kepler Capital Markets upgraded Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Recordati Industria Chimica E Farmaceutica has a consensus rating of “Buy”.

Recordati Industria Chimica E Farmaceutica Price Performance

Shares of Recordati Industria Chimica E Farmaceutica stock opened at $65.44 on Thursday. Recordati Industria Chimica E Farmaceutica has a twelve month low of $49.00 and a twelve month high of $65.44. The firm’s 50-day moving average price is $65.44 and its 200 day moving average price is $65.44. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 1.13.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.